A wealth of new molecules appeared recently for the treatment of Parkinson's disease. New galenic presentations of L-dopa (biphasic Madopar DR) and COMT inhibitors (tolcapone, entacapone) prolong the effects of L- dopa. New potent, well-tolerated dopaminergic agonists (pergolide, ropinirole, pramipexole, and cabergoline) broaden the possibilities treating early and late phases of the disease and may provide some neuroprotection. Finally subthalamic and pallidal stimulations offer major improvements for advanced patients with drug-resistant fluctuations, but, with uncertainty on long term effects. These procedures should stay in the hands of an experienced team of neurologists and neurosurgeons. Neurotransplantation and use of growth factors are still in preclinical phases.
|Number of pages||8|
|Journal||Medecine et Hygiene|
|Publication status||Published - May 13 1998|
ASJC Scopus subject areas